The size of the Cartilage Regeneration Market in Europe was valued USD 137.43 million in 2019 and is projected to be growing at a CAGR of 15.5%, to touch 282.49 million by 2024 during the forecast period 2019 - 2024.
The main function of cartilage is connecting bones together. It is found in the human body in areas like ear, nose, throat, rib cage and between the bones of the back. Cartilage tissue is vital because of the flexibility and stability of movement it provides. Hyaline Cartilage is the most widespread type of cartilage and makes up the embryonic skeleton.
The growth of the Europe Cartilage Regeneration Market is mainly driven by factors such as the increasing incidence of joint and bone disorders such as Osteoarthritis, which are a result of damage or wear and tear of connective tissues and the growing aging population with related connective tissue ailments. Furthermore, increase in the obese population and rising frequency of sports injuries & road accidents are set to boost market growth in the future.
However, unfavourable reimbursement policies and the high cost of therapy are the major restraints of market growth.
This research report segmented and sub-segmented the North America Cartilage Regeneration Market into the following categories and evaluated market size and forecast to each segment until 2024.
Notable companies leading the Europe Cartilage Regeneration Market Profiled in the Report are Zimmer Biomet Holdings, Inc. (U.S.), Vericel Corporation (U.S.), Smith & Nephew plc (U.K.), Osiris Therapeutics, Inc. (U.S.), and Arthrex Inc. (U.S.).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Type of Treatment
5.1.1 Introduction
5.1.2 Cell Based Approaches
5.1.2.1 Stem Cells
5.1.2.2 Growth Factor Technology
5.1.2.3 Chondrocyte Transplantation
5.1.3 Non-Cell Based Approaches
5.1.3.1 Cell Free Composites
5.1.3.2 Tissue Scaffolds
5.1.4 Y-o-Y Growth Analysis, By Type of Treatment
5.1.5 Market Attractiveness Analysis, By Type of Treatment
5.1.6 Market Share Analysis, By Type of Treatment
5.2 Application
5.2.1 Introduction
5.2.2 Hyaline Cartilage Regeneration
5.2.3 Fibrocartilage Regeneration
5.2.4 Y-o-Y Growth Analysis, By Application
5.2.5 Market Attractiveness Analysis, By Application
5.2.6 Market Share Analysis, By Application
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type of Treatment
6.1.3.3 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type of Treatment
6.1.4.3 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type of Treatment
6.1.5.3 By Application
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Zimmer Biomet Holdings
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Vericel Corporation
8.3 Smith & Nephew
8.4 Osiris Therapeutics
8.5 Arthrex
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
Related Reports
